Abstract:Co-delivery of multiple drugs with complementary anticancer mechanisms by nano-carriers offers an effective strategy to treat cancer. The combination of drugs with pro-apoptotic and anti-angiogenic activities is potentially effective in treating human hepatocellular carcinoma (HCC). Herein, we developed a co-delivery system for doxorubicin (Dox), a pro-apoptotic drug, and curcumin (Cur), a potent drug for antiangiogenesis, in pH-sensitive nanoparticles (NPs) constituted with amphiphilic poly(p-amino ester) copolymer. Dox & Cur co-loaded NPs ((D + C)/NPs) were prepared with optimized drug ratio, showing low polydispersity, high encapsulation efficiency, and enhanced release in the acidic environment of cancer cells. Furthermore, enhanced cellular internalization of cargoes delivered from (D + C)/NPs were observed in human liver cancer SMMC 7721 cells and human umbilical vein endothelial cells (HUVECs) compared to the use of free drugs. The (D + C)/NPs induced a high rate of apoptosis in SMMC 7721 cells through decreased mitochondrial membrane potential. Additionally, (D + C)/NPs exhibited stronger anti-angiogenic effects including inhibition of HUVEC proliferation, migration, invasion, and tube formation mediated VEGF pathway modulation in vitro and in vivo. Taken together, encapsulation of the pro-apoptotic drug Dox and antiangiogenic agent Cur in pH-sensitive NPs provides a promising strategy to effectively inhibit HCC progression in a synergistic manner.Statement of SignificanceThe combination of multiple drugs has been demonstrated to be more effective than single treatment. However, the different physicochemical and pharmacokinetic profiles of each drug render optimal delivery challenging. In view of the great delivery advantage of nanocarriers to unify the multiple drugs in vivo, stimulus-responsive nano-carriers are more crucial to increase efficacy and reduce toxicity from off-target exposure. Therefore, herein the pH-sensitive nanoparticles, composed by D-alpha-tocopheryl polyethylene glycol 1000-block-poly (beta-amino ester) (TPGS-PAE) polymers, have been fabricated for doxorubicin (Dox) and curcumin (Cur) co-delivery, which exhibited diverse anticancer approaches, i.e. proapoptosis and antiangiogenesis. The precise intracellular target site and effective drug combination concentration result in the enhanced antitumor efficiency and the reduced systematic toxicity of Dox. The co-encapsulation of the pro-apoptotic drug and antiangiogenic agent in pH-sensitive NPs provides a promising strategy to effectively inhibit malignant neoplasm progression in a synergistic manner. (C) 2017 Published by Elsevier Ltd on behalf of Acta Materialia Inc.

Co-delivery of Erlotinib and Doxorubicin by Ph-Sensitive Charge Conversion Nanocarrier for Synergistic Therapy.

Liposomes co-encapsulating doxorubicin and glucoevatromonoside derivative induce synergic cytotoxic response against breast cancer cell lines

A pH sensitive co-delivery system of siRNA and doxorubicin for pulmonary administration to B16F10 metastatic lung cancer

Co-delivery of Doxorubicin and Afatinib with Ph-Responsive Polymeric Nanovesicle for Enhanced Lung Cancer Therapy

Dual Ph-Responsive-charge-reversal Micelle Platform for Enhanced Anticancer Therapy

EGF-modified mPEG-PLGA-PLL nanoparticle for delivering doxorubicin combined with Bcl-2 siRNA as a potential treatment strategy for lung cancer.

Ph-Responsive Charge Switchable PEGylated Ε-Poly-l-lysine Polymeric Nanoparticles-Assisted Combination Therapy for Improving Breast Cancer Treatment.

A synergistic polyphosphoester-based co-delivery system of the anticancer drug doxorubicin and the tumor suppressor gene p53 for lung cancer therapy

A Codelivery System of Anticancer Drug Doxorubicin and Tumor-Suppressor Gene P53 Based on Polyphosphoester for Lung Cancer Therapy

Synergistic Combination Chemotherapy of Lung Cancer: Cisplatin and Doxorubicin Conjugated Prodrug Loaded, Glutathione and pH Sensitive Nanocarriers

Co-delivery of doxorubicin and paclitaxel by PEG-polypeptide nanovehicle for the treatment of non-small cell lung cancer.

Co-delivery of Doxorubicin and Arsenite with Reduction and Ph Dual-Sensitive Vesicle for Synergistic Cancer Therapy

Co-delivery of DOX and PDTC by Ph-Sensitive Nanoparticles to Overcome Multidrug Resistance in Breast Cancer.

Effective co-delivery of doxorubicin and dasatinib using a PEG-Fmoc nanocarrier for combination cancer chemotherapy

Nanoscaled Poly(l-Glutamic Acid)/doxorubicin-Amphiphile Complex As Ph-Responsive Drug Delivery System for Effective Treatment of Nonsmall Cell Lung Cancer.

Dual-pH Responsive Micelle Platform for Co-Delivery of Axitinib and Doxorubicin

Reduction and Ph Dual-Sensitive Nanovesicles Co-Delivering Doxorubicin and Gefitinib for Effective Tumor Therapy

Multistage pH-responsive codelivery liposomal platform for synergistic cancer therapy

Ph-Sensitive Polymeric Nanoparticles for Co-Delivery of Doxorubicin and Curcumin to Treat Cancer Via Enhanced Pro-Apoptotic and Anti-Angiogenic Activities

Co-delivery of Doxorubicin and Curcumin with Polypeptide Nanocarrier for Synergistic Lymphoma Therapy

Codelivery of doxorubicin and triptolide with reduction-sensitive lipid-polymer hybrid nanoparticles for in vitro and in vivo synergistic cancer treatment.